...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Interferences with Two-site Immunoassays by Human Anti-mouse Antibodies Formed by Patients Treated with Monoclonal Antibodies: Comparison of Different Blocking Reagents
【24h】

Interferences with Two-site Immunoassays by Human Anti-mouse Antibodies Formed by Patients Treated with Monoclonal Antibodies: Comparison of Different Blocking Reagents

机译:单克隆抗体治疗的患者形成的人抗小鼠抗体对两点免疫测定的干扰:不同阻断剂的比较

获取原文
           

摘要

The most widely used approach for reducing interferences with two-site immunoassays by human anti-mouse antibodies (HAMAs) developed by many patients after exposure to murine immunoglobulins is to include high amounts of nonspecific mouse IgG within the assay buffer (1)(2). Recently, M?ssner et al. (3) have developed a polymerized form of murine IgG (MAK33), which they found to be superior to normal mouse IgG for blocking HAMA interferences. In contrast, we observed false-positive values for the cancer antigen 125 (CA 125), because of HAMA interferences in samples from ovarian cancer patients treated with the anti-CA-125 antibody OC125, which could be corrected by preincubation with mouse IgG but not with MAK33 (4). The aim of the present study was to examine whether treatment with other monoclonal antibodies gives rise to additional HAMAs that are insensitive to MAK33 and to further characterize this specific HAMA response.Sixty-four serum samples were obtained from 51 ovarian cancer patients who, in the course of several clinical studies (5)(6)(7)(8), had received multiple infusions of one of four murine monoclonal antibodies: OC125 (16 patients), B43.13 (8 patients), ACA125 (18 patients), and B72.3 (9 patients). The procedures followed in this study were in accordance with the standards of the ethical committee of our faculty. The interfering HAMA activity of the samples was quantified with a bridging HAMA assay (HAMA-ELISA medac, Medac) involving polyclonal murine IgG in both capture and detection steps before and after preincubation (30 min at room temperature) with the following: (a) polyMAK-33 (MAK33), a polymerized murine IgG1,κ preparation (gift of Boehringer Mannheim, Mannheim, Germany); (b) Immunoglobulin Inhibiting Reagent (IIR) a formulation of immunoglobulins targeted against HAMAs (gift of Bioreclamation, East Meadow, NY); (c) polyclonal mouse IgG (reagent grade, Sigma Chemical Co.); and (d) mouse IgG of different …
机译:减少使用鼠免疫球蛋白后许多患者开发的人抗小鼠抗体(HAMA)对两点免疫测定产生干扰的最广泛使用的方法是在测定缓冲液中包含大量非特异性小鼠IgG(1)(2) 。最近,M?ssner等人。 (3)已开发出鼠IgG(MAK33)的聚合形式,发现它们在阻断HAMA干扰方面优于正常小鼠IgG。相反,我们观察到癌症抗原125(CA 125)的假阳性值,因为HAMA干扰了抗CA-125抗体OC125处理的卵巢癌患者的样品,可以通过与小鼠IgG的预孵育来纠正此错误,但不适用于MAK33(4)。本研究的目的是检查用其他单克隆抗体治疗是否会引起对MAK33不敏感的其他HAMA,并进一步表征这种特定的HAMA反应。从51名卵巢癌患者中获得了64份血清样本。几项临床研究的过程(5)(6)(7)(8),已多次输注四种鼠类单克隆抗体之一:OC125(16例患者),B43.13(8例患者),ACA125(18例患者),和B72.3(9例)。这项研究遵循的程序符合我们教师伦理委员会的标准。通过预孵育前后(室温下30分钟)在捕获和检测步骤中涉及多克隆鼠IgG的桥接HAMA分析(HAMA-ELISA medac,Medac)对样品的干扰HAMA活性进行定量,方法如下:(a) polyMAK-33(MAK33),一种聚合的鼠类IgG1,κ制剂(Boehringer Mannheim的礼物,德国曼海姆); (b)免疫球蛋白抑制剂(IIR),一种针对HAMA的免疫球蛋白制剂(Bioreclamation公司的礼物,纽约州东梅多); (c)多克隆小鼠IgG(试剂级,Sigma Chemical Co.); (d)不同……的小鼠IgG

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号